43 related articles for article (PubMed ID: 24127858)
1. A New Synthetic Route to Polyhydrogenated Pyrrolo[3,4-b]pyrroles by the Domino Reaction of 3-Bromopyrrole-2,5-Diones with Aminocrotonic Acid Esters.
Shikhaliev K; Sabynin A; Sekirin V; Krysin M; Zubkov F; Yankina K
Molecules; 2017 Nov; 22(11):. PubMed ID: 29165400
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of Linearly Fused Benzodipyrrole Based Organic Materials.
Vlasselaer M; Dehaen W
Molecules; 2016 Jun; 21(6):. PubMed ID: 27322228
[TBL] [Abstract][Full Text] [Related]
3. An Expedient Synthesis of Murrayaquinone A via a Novel Oxidative Free Radical Reaction.
McDonald JW; Miller JE; Kim M; Velu SE
Tetrahedron Lett; 2018 Feb; 59(6):550-553. PubMed ID: 29736091
[TBL] [Abstract][Full Text] [Related]
4. Recent synthetic strategies for the construction of functionalized carbazoles and their heterocyclic motifs enabled by Lewis acids.
Kumar MP; G M; Amaladass P; Manikandan C; Dhayalan V
RSC Adv; 2023 Oct; 13(46):32596-32626. PubMed ID: 37936643
[TBL] [Abstract][Full Text] [Related]
5. [RhCp*Cl
Singh Chauhan AN; Mali G; Dua G; Samant P; Kumar A; Erande RD
ACS Omega; 2023 Aug; 8(31):27894-27919. PubMed ID: 37576617
[TBL] [Abstract][Full Text] [Related]
6. Coupling Reactions of Anhydro-Aldose Tosylhydrazones with Boronic Acids.
Kaszás T; Baráth BÁ; Balázs B; Blága T; Juhász L; Somsák L; Tóth M
Molecules; 2022 Mar; 27(6):. PubMed ID: 35335162
[TBL] [Abstract][Full Text] [Related]
7. Carbazole scaffolds in cancer therapy: a review from 2012 to 2018.
Issa S; Prandina A; Bedel N; Rongved P; Yous S; Le Borgne M; Bouaziz Z
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1321-1346. PubMed ID: 31328585
[TBL] [Abstract][Full Text] [Related]
8. Function through bio-inspired, synthesis-informed design: step-economical syntheses of designed kinase inhibitors†Dedicated to Max Malacria, a friend and scholar whose science and creative contributions to step-economical synthesis have inspired us all and moved the field closer to the ideal.‡Electronic supplementary information (ESI) available: Synthetic procedures and spectral data. See DOI: 10.1039/c4qo00228hClick here for additional data file.
Wender PA; Axtman AD; Golden JE; Kee JM; Sirois LE; Quiroz RV; Stevens MC
Org Chem Front; 2014 Dec; 1(10):1166-1171. PubMed ID: 25632347
[TBL] [Abstract][Full Text] [Related]
9. Pyrrolocarbazoles as checkpoint 1 kinase inhibitors.
Hénon H; Conchon E; Hugon B; Messaoudi S; Golsteyn RM; Prudhomme M
Anticancer Agents Med Chem; 2008 Aug; 8(6):577-97. PubMed ID: 18690823
[TBL] [Abstract][Full Text] [Related]
10. Marine pyrrolocarbazoles and analogues: synthesis and kinase inhibition.
Deslandes S; Chassaing S; Delfourne E
Mar Drugs; 2009 Dec; 7(4):754-86. PubMed ID: 20098609
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of C-glycosyl pyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as a scaffold for check point kinase 1 inhibitors.
Ichikawa S; Tatebayashi N; Matsuda A
J Org Chem; 2013 Dec; 78(23):12065-75. PubMed ID: 24127858
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of 5-substituted 9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as check point 1 kinase inhibitors.
Sako Y; Ichikawa S; Osada A; Matsuda A
Bioorg Med Chem; 2010 Nov; 18(22):7878-89. PubMed ID: 20943405
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and structure-activity relationships of soluble 8-substituted 4-(2-chlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as inhibitors of the Wee1 and Chk1 checkpoint kinases.
Smaill JB; Lee HH; Palmer BD; Thompson AM; Squire CJ; Baker EN; Booth RJ; Kraker A; Hook K; Denny WA
Bioorg Med Chem Lett; 2008 Feb; 18(3):929-33. PubMed ID: 18191399
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, in vitro antiproliferative activities, and Chk1 inhibitory properties of pyrrolo[3,4-a]carbazole-1,3-diones, pyrrolo[3,4-c]carbazole-1,3-diones, and 2-aminopyridazino[3,4-a]pyrrolo[3,4-c]carbazole-1,3,4,7-tetraone.
Conchon E; Anizon F; Aboab B; Golsteyn RM; Léonce S; Pfeiffer B; Prudhomme M
Eur J Med Chem; 2008 Feb; 43(2):282-92. PubMed ID: 17502122
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
